Dr Juan Carlos Castillo participates in the Dexeus Congress to talk about the equivalence of a new drug for ovarian stimulation.

Dr Juan Carlos Castillo, scientific director of Instituto Bernabeu, participated in the 46th Dexeus International Congress, held in Barcelona and organised by Ferring. During his speech, Dr Castillo focused on the dose equivalence of the follitropin delta hormone.

Dr Castillo’s conclusions are based on the importance of personalising ovarian stimulation according to each patient’s specific needs and wishes, while minimising potential risks. In addition, he highlighted that the use of this drug would be beneficial in cases of cryopreservation and egg donation, as well as in patients with low response and in families wishing to have more than one child.

On the other hand, he emphasised the need for a common reference unit to understand proposed doses with different gonadotrophins, given the abundance of existing clinical protocols for ovarian stimulation. In this regard, he stated that the application of the dose equivalence factor would streamline the transition of patients between protocols using different gonadotrophins in successive cycles, thus mitigating the risk of misinterpretation.

On the other hand, Dr Cecilia Quetglás, from Instituto Bernabeu Palma de Mallorca, and Dr Paula Moral and Dr Begoña Alcaraz, from Instituto Bernabeu Alicante, also participated in the congress.